Certain diseases, including Alzheimer’s, are currently considered ‘undruggable’ because traditional small molecule drugs can’t interfere with the proteins responsible for the illnesses. But a new technique that specifically targets and breaks apart certain proteins — rather than just interfering with them — may offer a pathway toward treatment. Researchers have now designed a compound that targets and breaks down a post-translationally modified protein closely associated with Alzheimer’s disease.
